PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
Chemotherapy
Endometrial cancer
Immune Checkpoint inhibitors
Mismatch repair–deficient
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Nov 2023
29 Nov 2023
Historique:
received:
06
09
2023
accepted:
18
11
2023
medline:
1
12
2023
pubmed:
30
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Paclitaxel and carboplatin is the standard chemotherapy for the treatment of advanced or recurrent endometrial cancer. However, the benefit of adding programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors to chemotherapy is still unclear. We searched PubMed, Scopus, Cochrane, and Web of Science databases for randomized controlled trials that investigated PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer. We computed hazard ratios (HRs) or risk ratios (RRs) for binary endpoints, with 95% confidence intervals (CIs). We used DerSimonian and Laird random-effect models for all endpoints. Heterogeneity was assessed using I A total of three studies and 1,431 patients were included. Compared with carboplatin plus paclitaxel-based chemotherapy, progression-free survival (PFS) rate (HR 0.32; 95% CI 0.23-0.44; p < 0.001) and overall survival (OS) at 30 months (RR 3.13; 95% CI 1.26-7.78; p = 0.01) were significant in favor of the PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel group in the mismatch repair-deficient subgroup. However, there were no significant differences in the mismatch repair-proficient subgroup for PFS (HR 0.74; 95% CI 0.50-1.08; p = 0.117) or OS at 30 months (RR 2.24; 95% CI 0.79-6.39; p = 0.13). Immunotherapy plus carboplatin-paclitaxel increased significantly PFS and OS among patients with advanced or recurrent endometrial cancer, with a significant benefit in the mismatch repair-deficient and high microsatellite instability population.
Sections du résumé
BACKGROUND
BACKGROUND
Paclitaxel and carboplatin is the standard chemotherapy for the treatment of advanced or recurrent endometrial cancer. However, the benefit of adding programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors to chemotherapy is still unclear.
METHOD
METHODS
We searched PubMed, Scopus, Cochrane, and Web of Science databases for randomized controlled trials that investigated PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer. We computed hazard ratios (HRs) or risk ratios (RRs) for binary endpoints, with 95% confidence intervals (CIs). We used DerSimonian and Laird random-effect models for all endpoints. Heterogeneity was assessed using I
RESULTS
RESULTS
A total of three studies and 1,431 patients were included. Compared with carboplatin plus paclitaxel-based chemotherapy, progression-free survival (PFS) rate (HR 0.32; 95% CI 0.23-0.44; p < 0.001) and overall survival (OS) at 30 months (RR 3.13; 95% CI 1.26-7.78; p = 0.01) were significant in favor of the PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel group in the mismatch repair-deficient subgroup. However, there were no significant differences in the mismatch repair-proficient subgroup for PFS (HR 0.74; 95% CI 0.50-1.08; p = 0.117) or OS at 30 months (RR 2.24; 95% CI 0.79-6.39; p = 0.13).
CONCLUSION
CONCLUSIONS
Immunotherapy plus carboplatin-paclitaxel increased significantly PFS and OS among patients with advanced or recurrent endometrial cancer, with a significant benefit in the mismatch repair-deficient and high microsatellite instability population.
Identifiants
pubmed: 38031003
doi: 10.1186/s12885-023-11654-z
pii: 10.1186/s12885-023-11654-z
pmc: PMC10688003
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
B7-H1 Antigen
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1166Informations de copyright
© 2023. The Author(s).
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Clin Cancer Res. 2016 Feb 15;22(4):813-20
pubmed: 26880610
Oncoimmunology. 2017 Jun 16;6(7):e1331807
pubmed: 28811975
JAMA Oncol. 2020 Jun 1;6(6):831-838
pubmed: 32379280
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Cancers (Basel). 2022 Apr 29;14(9):
pubmed: 35565369
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Exp Dermatol. 2022 Jun;31(6):869-877
pubmed: 34994009
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
Gynecol Oncol. 2021 May;161(2):573-580
pubmed: 33551200
J Clin Oncol. 2022 Mar 1;40(7):752-761
pubmed: 34990208
Clin Cancer Res. 2009 Oct 15;15(20):6341-7
pubmed: 19825956
J Clin Invest. 2011 Aug;121(8):3100-8
pubmed: 21765211
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Ann Oncol. 2019 Aug 1;30(8):1232-1243
pubmed: 31056702
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2019 Oct 20;37(30):2786-2794
pubmed: 31461377
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):803-8
pubmed: 17944917
Front Immunol. 2019 Aug 06;10:1816
pubmed: 31447840
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35064011
Obstet Gynecol. 2022 Mar 1;139(3):440-442
pubmed: 35115431
Cancer. 2016 Sep 15;122(18):2787-98
pubmed: 27308732
Oncoimmunology. 2013 Oct 1;2(10):e27025
pubmed: 24353914
Cancer Immunol Immunother. 2014 Jun;63(6):545-57
pubmed: 24658839
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
BMC Med Res Methodol. 2014 Feb 18;14:25
pubmed: 24548571
Trends Cancer. 2016 Mar;2(3):121-133
pubmed: 28741532
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Clin Oncol. 2017 Aug 1;35(22):2535-2541
pubmed: 28489510
J Hematol Oncol. 2022 Jul 16;15(1):95
pubmed: 35842707
N Engl J Med. 2023 Jun 8;388(23):2159-2170
pubmed: 36972022
N Engl J Med. 2023 Jun 8;388(23):2145-2158
pubmed: 36972026
Clin Cancer Res. 2020 Oct 1;26(19):5062-5067
pubmed: 32295834
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Gastrointest Endosc Clin N Am. 2022 Apr;32(2):177-194
pubmed: 35361330
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
J Clin Oncol. 2020 Nov 20;38(33):3841-3850
pubmed: 33078978
Lancet Oncol. 2023 Mar;24(3):286-296
pubmed: 37052965
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120